RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Brigham and Women's Hospital
Novartis
Information provided by (Responsible Party):
Richard Stone, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00819546
First received: January 8, 2009
Last updated: February 3, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)